2491: Parental concerns about child participation in s reflect a need to move beyond traditional notions of trust and race by Cunningham-Erves, Jennifer et al.
Georgia Southern University 
Digital Commons@Georgia Southern 
Health Policy and Community Health Faculty 
Publications 
Health Policy and Community Health, 
Department of 
5-10-2018 
2491: Parental concerns about child participation in s reflect a 
need to move beyond traditional notions of trust and race 
Jennifer Cunningham-Erves 
Meharry Medical College, jerves@mmc.edu 
Tilicia Mayo-Gamble 
Georgia Southern University, Jiann-Ping Hsu College of Public Health, 
tmayogamble@georgiasouthern.edu 
Consuelo H. Wilkins 
Meharry Vanderbilt Alliance 
Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/hpmb-facpubs 
 Part of the Community Health Commons, Community Health and Preventive Medicine Commons, and 
the Health Policy Commons 
Recommended Citation 
Cunningham-Erves, Jennifer, Tilicia Mayo-Gamble, Consuelo H. Wilkins. 2018. "2491: Parental concerns 
about child participation in s reflect a need to move beyond traditional notions of trust and race." Journal 




This conference abstract is brought to you for free and open access by the Health Policy and Community Health, 
Department of at Digital Commons@Georgia Southern. It has been accepted for inclusion in Health Policy and 
Community Health Faculty Publications by an authorized administrator of Digital Commons@Georgia Southern. For 
more information, please contact digitalcommons@georgiasouthern.edu. 
hemodynamics as a measure of responsiveness to cocaine infusions. This
procedure also provides a benchmark to evaluate the potential impact of
pharmacologic treatments on cocaine-induced hemodynamic changes and
patient perceptions of cocaine response.
2491
Parental concerns about child participation in s
reflect a need to move beyond traditional notions of
trust and race
Jennifer Erves, Tilicia Mayo-Gamble and Consuelo Hopkins Wilkins
Vanderbilt University, Nashville, TN, USA
OBJECTIVES/SPECIFIC AIMS: The objective of this study was to identify factors
influencing parental willingness of adolescent participation in clinical trials.
METHODS/STUDY POPULATION: We applied community engaged research
principles to conduct a theory-based, cross-sectional study of parental
willingness. Parents (N=307) were given a survey from November 2014 to
April 2015. Factors influencing parental willingness were identified using binary
logistic regression. SPSS version 22.0 was used to perform analyses, and p<0.05
was considered statistically significant. RESULTS/ANTICIPATED RESULTS:
The most impactful factor on willingness was Advantages of Adolescent Clinical
Research (p = .001), followed by Disadvantages of Clinical Research (p = .006),
Knowledge of Adolescent Clinical Trials (p = 0.029), and Perceived Health
Status of Adolescent (p = .036). In further exploring the influence of Perceived
Advantages and Perceived Disadvantages, “My child will do something to help
others.” (p = .026) and “My child is too young to participate in a clinical trial.”
was the only significant Perceived Disadvantage (p = .001) were significantly
associated with parental willingness. DISCUSSION/SIGNIFICANCE OF
IMPACT: Improving parental knowledge and understanding of adolescent
clinical trials, the advantages and disadvantages of adolescent participation, and
the health status requirements for child participation are important factors to
address when influencing parental willingness to allow adolescents to
participate in clinical trials. Recruitment strategies that incorporate this
information could improve future adolescent participation in clinical trials,
ultimately promoting adolescent health and disease prevention.
2544
Dietary polyunsaturated fatty acid consumption is
associated with improved body composition in
nonalcoholic steatohepatitis patients
Hayley Billingsley, Salvatore Carbone, Justin M. Canada, Leo Buckley,
Dave L. Dixon, Dinesh Kadariya, Sofanit Dessie, Benjamin W. Van
Tassell, Antonio Abbate and Mohammad Siddiqui
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES/SPECIFIC AIMS: Nonalcoholic steatohepatitis (NASH) is a common
cause of chronic liver disease in the United States characterized by fat accumulation,
inflammation, and fibrosis. Higher amounts of fat-free mass (FFM) and lower
amounts of fat mass (FM) have been associated with better outcomes in several
chronic diseases, recently also in NASH. Body composition is highly influenced by
diet. However, the role of diet on body composition in patients with NASH is
largely unknown.We hypothesized that consumption of polyunsaturated fatty acids
(PUFA), healthy fatty acids mainly found in fish, nuts, and some vegetable oils, is
associated with improved body composition, specifically greater FFM and lower
FM, in NASH patients. METHODS/STUDY POPULATION: In total, 13 patients
with histologically confirmed NASH underwent body composition testing via
bioelectrical impedance analysis to estimate FFM% (% of body weight), FM% (% of
body weight), and FFM/FM ratio. PUFA and saturated fat consumption was
determined by standardized 5-pass 24-hour dietary recall. Correlations were
computed using the Spearman rank test. RESULTS/ANTICIPATED RESULTS:
Median body mass index (BMI) was 35.7 kg/m2 (32.8–42.7), median age of the
sample was 50 years (46.3–57.3), and 73% were female. Median percent of calories
from polyunsaturated fat was 6.8% (5.4–9.6). Percent of calories from PUFA was
positively and significantly associated with greater FFM% (R=0.56, p=0.049),
lower FM% (R= −0.59, p=0.035), and greater FFM/FM ratio (R=0.58, p=0.037).
Additionally, a higher PUFA to saturated fatty acids ratio was also significantly
correlated with greater FFM% (R=0.58, p=0.039), lower FM% (R= −0.64,
p=0.020), and greater FFM/FM ratio (R=0.57, p=0.043). DISCUSSION/
SIGNIFICANCE OF IMPACT: In patients with NASH, the consumption of PUFA
is associated with higher FFM and lower FM, which suggests a protective role of
these nutrients on body composition. A larger study on patients with NASH is
warranted to confirm our findings on PUFA consumption and body composition,




iobio: From academic project to commercial
enterprise
Alistair N. Ward, Chase Miller and Gabor Marth
The University of Utah School of Medicine, Salt Lake City, UT, USA
OBJECTIVES/SPECIFIC AIMS: The iobio project enables anyone (eg, diagnos-
ticians, MDs, genetic counselors, citizen scientists) to perform useful analysis of
genomic data, without a need to rely on bioinformaticians. iobio uses a novel
real-time analysis framework, coupled with powerful visualizations delivered in
a standard web browser. The project successfully supports free academic/
nonprofit users, but occasions exist where it is more applicable for the project
to be delivered commercially. Frameshift Genomics is developing commercial
applications and functionality, which will exist alongside and in coordination
with the academic project. These products will be marketed to large institutions
including genome institutes, hospitals, diagnostic labs etc., but also to individual
users who do not have access to large compute resources, or bioinformatic
analysts, and everything in between. METHODS/STUDY POPULATION: The
commercial iobio project under Frameshift Genomics aims to develop
applications and features that cannot be successfully supported by an academic
model. For example, when analyses are scaled up to processing of extremely
large data sets, a commercial product with access to compute resources makes
more sense than an academic tool. Bam.iobio is an application that samples data
from sequencing alignment files, taking seconds to generate and visualize
statistics representative of the entire file. This app is offered for free
academically. When analysis involves thousands of such files, however, the
commercial application, multibam.iobio, is more suitable. Other examples,
including support for licensed third-party software and permitting extensive
computation via cloud platforms, can also only be reasonably be supported via
commercial software. Finally, development of commercial applications is driving
adoption of more rigorous testing platforms, delivering more robust products.
A particular strength of the iobio platform is allowing non-bioinformaticians to
understand their data, for example providing quality control functionality
providing confidence in data sets and the conclusions drawn from them. Such
analyses are critical to all users of genomic data, and the iobio platform is ideally
suited to provide an intuitive, integrated framework for performing them.
RESULTS/ANTICIPATED RESULTS: The iobio project has been readily
adopted by many in the community and shows significant promise for
democratizing genomic analysis. Work is ongoing, supported by NIH small
business grants, to develop commercial applications that will be marketed to
analysts and medical professionals from large genome institutes and universities,
to individual project users and citizen scientists. DISCUSSION/SIGNIFICANCE
OF IMPACT: There are currently a number of iobio tools available
academically, and they have been embraced by many in the genomics
community. In fact, a number of popular platforms (eg, Galaxy, the International
Cancer Genome Consortium (ICGC) data portal, mygene2 at the University of
Washington) have incorporated iobio tools into their own platforms. To date,
the gene.iobio variant interrogation tool has been used in a number of
diagnostic projects, aiding identification of putative causative variants, and the
pre-release version of the commercial multibam.iobio tool has been critical in
unearthing data quality problems in project level data.
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I-Corps at NCATS: Toward entrepreneurial training
for clinical and translational investigators and lessons
learned in team-based customer and stakeholder
discovery
Molly Wasko, Elaine Morrato, Nicholas Kenyon, Suhrud Rajguru,
Bruce Conway, Sara Love, Nate Hafer, Pamela Bhatti, Jonathan Fay
and Seth Zonies
OBJECTIVES/SPECIFIC AIMS: The goal of this abstract/presentation is to share
lessons learned from participation in the NIH SBIR I-Corps Train-The-Trainer
Program, discuss our experiences offering programs at our local institutions,
and communicate our plans to develop an I-Corps@NCATS program that can
be disseminated across the CTSA network. We believe that an I-Corps@
NCATS programwill enhance the process of scientific translation by taking best
practices from NSF I-Corps and adapting the program to meet the needs of
biomedical scientists in academic medical centers. By integrating I-Corps@
NCATS training, we hypothesize that the clinical and translational investigator
base will be better prepared to identify new innovations and to accelerate
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